Loading...
Adding anti–epidermal growth factor receptor (EGFR) agents to first- and second-line chemotherapy has been shown to improve response, progression-free survival (PFS), and overall survival (OS) in metastatic KRAS-wild type colorectal cancer (CRC). However, a benefit for these agents has not been consistent across all studies.
To assess the effect of adding the EGFR-targeted monoclonal antibody cetuximab to continuous or intermittent first-line 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (Nordic FLOX) chemotherapy, investigators conducted an international, randomized, phase III trial involving 566 evaluable patients with metastatic CRC (96% with performance status 0–1; 59% male). KRAS mutations were found in 39% of tumor samples from 49…